MCID: VSC018
MIFTS: 34

Visceral Steatosis

Categories: Liver diseases, Rare diseases

Aliases & Classifications for Visceral Steatosis

MalaCards integrated aliases for Visceral Steatosis:

Name: Visceral Steatosis 53 55
Fatty Metamorphosis of Viscera 53 72
Fatal Neonatal Hepatic Steatosis 53
White Liver Disease 53
Steatosis of Liver 53
Steatohepatitis 72

Classifications:



External Ids:

UMLS 72 C0341447 C2711227

Summaries for Visceral Steatosis

MalaCards based summary : Visceral Steatosis, also known as fatty metamorphosis of viscera, is related to visceral steatosis, congenital and liver disease. An important gene associated with Visceral Steatosis is SLC22A5 (Solute Carrier Family 22 Member 5), and among its related pathways/superpathways are AMP-activated Protein Kinase (AMPK) Signaling and AMPK Enzyme Complex Pathway. The drugs Selenium and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart.

Related Diseases for Visceral Steatosis

Graphical network of the top 20 diseases related to Visceral Steatosis:



Diseases related to Visceral Steatosis

Symptoms & Phenotypes for Visceral Steatosis

Drugs & Therapeutics for Visceral Steatosis

Drugs for Visceral Steatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 277)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
2
Liraglutide Approved Phase 4 204656-20-2 44147092
3
Glucagon Approved Phase 4 16941-32-5
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051
5
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Ribavirin Approved Phase 4 36791-04-5 37542
8
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
9
Insulin Detemir Approved Phase 4 169148-63-4 5311023
10
Insulin Aspart Approved Phase 4 116094-23-6 16132418
11
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
12
Metformin Approved Phase 4 657-24-9 4091 14219
13
Alogliptin Approved Phase 4 850649-61-5 11450633
14
Testosterone enanthate Approved Phase 4 315-37-7 9416
15
Methyltestosterone Approved Phase 4 58-18-4 6010
16
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
17
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
18
Dulaglutide Approved, Investigational Phase 4 923950-08-7
19
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
20
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
21
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
22 Anti-HIV Agents Phase 4
23 Antiviral Agents Phase 4
24 Anti-Retroviral Agents Phase 4
25 Integrase Inhibitors Phase 4
26 Raltegravir Potassium Phase 4
27 HIV Integrase Inhibitors Phase 4
28 Alpha-lipoic Acid Phase 4
29 Thioctic Acid Phase 4
30 Anti-Obesity Agents Phase 4
31 Interferon alpha-2 Phase 4
32 Interferon-alpha Phase 4
33 interferons Phase 4
34 Protein Kinase Inhibitors Phase 4
35 Pharmaceutical Solutions Phase 4
36 Antibodies Phase 4
37 Immunologic Factors Phase 4
38 Immunoglobulins Phase 4
39 Glucagon-Like Peptide 1 Phase 4
40 Androgens Phase 4
41 Anabolic Agents Phase 4
42 Antineoplastic Agents, Hormonal Phase 4
43 Testosterone 17 beta-cypionate Phase 4
44 Immunoglobulin Fc Fragments Phase 4
45 Gastrointestinal Agents Phase 4
46 Anti-Infective Agents Phase 4
47 Anti-Bacterial Agents Phase 4
48
Propranolol Approved, Investigational Phase 3 525-66-6 4946
49
Tocopherol Approved, Investigational Phase 2, Phase 3 1406-66-2, 54-28-4 14986
50
Losartan Approved Phase 3 114798-26-4 3961

Interventional clinical trials:

(show top 50) (show all 466)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
3 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
4 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
5 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
6 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
7 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
8 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
9 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
10 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
11 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
12 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
13 Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition. Completed NCT00522730 Phase 4
14 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon
15 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
16 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
17 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
18 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
19 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
20 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Not yet recruiting NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
21 A Multicentre Controlled and Randomized Study Assessing the Effect of Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement Alone in Patients With Type 2 Diabetes and Carriers of a Non-alcoholic Steatohepatitis Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
22 52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters Not yet recruiting NCT03851627 Phase 4 Testosterone Undecanoate;Placebo
23 RiFL:Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? Terminated NCT01355575 Phase 4 Rifaximin
24 Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection Terminated NCT00742326 Phase 4 Pioglitazone;Placebo
25 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
26 Regression of Fatty Heart by Valsartan Therapy Withdrawn NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
27 Pilot Project Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI Withdrawn NCT02263677 Phase 4 Sitagliptin
28 Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD) Unknown status NCT00303537 Phase 2, Phase 3 metformin
29 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
30 A Randomised Controlled Trial of Vitamin D Plus Plus Lifestyle Versus Lifestyle in Patients With Non-alcoholic Steatohepatitis:Effect on Liver Histology and Metabolic Parameters Unknown status NCT01623024 Phase 3 Vitamin D
31 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
32 Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3 Pioglitazone;Matching placebo
33 Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized, Controlled and Open Label Study Completed NCT00509418 Phase 3
34 Efficacy and Safety of Diamel, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized and Double Blind Controlled Study Completed NCT00820651 Phase 3
35 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed NCT03053063 Phase 3 SEL;Placebo
36 The Effects of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
37 S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis Completed NCT00108589 Phase 3 S-adenosylmethionine
38 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Completed NCT03053050 Phase 3 SEL;Placebo
39 A Randomised, Controlled Trial of Losartan as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis Completed NCT01051219 Phase 3 Losartan
40 Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Non-treated Matched Healthy Volunteers as Control Group Completed NCT01754714 Phase 3 SAMe 1000 mg;SAMe 1500 mg;SAMe 2000 mg
41 The Effects of Flaxseed Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Completed NCT02395900 Phase 2, Phase 3
42 Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT00681408 Phase 2, Phase 3 Omega 3 Fish Oil supplements;Placebo
43 The Effect of Pentoxifylline on Nonalcoholic Steatohepatitis (NASH) Completed NCT00267670 Phase 2, Phase 3 Pentoxifylline;Placebo
44 Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3 Metformin;Matching placebo
45 Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables. Completed NCT01245608 Phase 3 Polypill
46 The Effects of Resveratrol Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
47 Polyunsaturated Fatty Acid (Pufa) Omega 3 in the Reduction of the Inflammatory Component of the Nonalcoholic Steatohepatitis (Nash):Randomized Placebo Controlled Study Completed NCT01992809 Phase 3
48 Study of Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Completed NCT01934777 Phase 3 Docosahexaenoic Acid plus Vitamin E plus choline;placebo pearls
49 Role of Exenatide in Treatment of NASH-a Pilot Study Completed NCT00650546 Phase 2, Phase 3 Exenatide
50 An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Completed NCT01371825 Phase 2, Phase 3 Sebelipase alfa (SBC-102)

Search NIH Clinical Center for Visceral Steatosis

Genetic Tests for Visceral Steatosis

Anatomical Context for Visceral Steatosis

MalaCards organs/tissues related to Visceral Steatosis:

41
Liver, Testes, Heart, Kidney, Endothelial, Spleen, Skeletal Muscle

Publications for Visceral Steatosis

Articles related to Visceral Steatosis:

(show top 50) (show all 73)
# Title Authors PMID Year
1
Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. 9 38
16754783 2006
2
Expression and distribution of OCTN2 in mouse epididymis and its association with obstructive azoospermia in juvenile visceral steatosis mice. 9 38
16734862 2006
3
[Biopharmaceutical studies on molecular mechanisms of membrane transport]. 9 38
12510384 2002
4
A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. 9 38
9837751 1998
5
Sexual dimorphism of lipid metabolism in very long-chain acyl-CoA dehydrogenase deficient (VLCAD-/-) mice in response to medium-chain triglycerides (MCT). 38
25887160 2015
6
Hepatic toxicity of dronedarone in mice: role of mitochondrial β-oxidation. 38
24881592 2014
7
Carnitine is necessary to maintain the phenotype and function of brown adipose tissue. 38
21321536 2011
8
Induction of PDK4 in the heart muscle of JVS mice, an animal model of systemic carnitine deficiency, does not appear to reduce glucose utilization by the heart. 38
21190881 2011
9
[Study on the novel factors regulating mitochondrial dynamics]. 38
21048415 2010
10
Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. 38
19821448 2009
11
Failure of the feeding response to fasting in carnitine-deficient juvenile visceral steatosis (JVS) mice: involvement of defective acyl-ghrelin secretion and enhanced corticotropin-releasing factor signaling in the hypothalamus. 38
19744557 2009
12
Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice. 38
19220985 2009
13
Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. 38
17986647 2008
14
Effect of carnitine deprivation on carnitine homeostasis and energy metabolism in mice with systemic carnitine deficiency. 38
18417958 2008
15
Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. 38
18574325 2008
16
Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. 38
17884651 2007
17
Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation. 38
17664396 2007
18
Prolonged effect of single carnitine administration on fasted carnitine-deficient JVS mice regarding their locomotor activity and energy expenditure. 38
17027329 2006
19
Regulation of mitochondrial morphology and cell survival by Mitogenin I and mitochondrial single-stranded DNA binding protein. 38
16860483 2006
20
Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency. 38
16546150 2006
21
Fasting-induced reduction in locomotor activity and reduced response of orexin neurons in carnitine-deficient mice. 38
16540195 2006
22
Attenuation of cardiac hypertrophy in carnitine-deficient juvenile visceral steatosis (JVS) mice achieved by lowering dietary lipid. 38
16452314 2006
23
Dietary fish oil attenuates cardiac hypertrophy in lipotoxic cardiomyopathy due to systemic carnitine deficiency. 38
15963478 2005
24
Identification of the up- and down-regulated genes in the heart of juvenile visceral steatosis mice. 38
15056854 2004
25
Impact of alpha-tocopherol on cardiac hypertrophy due to energy metabolism disorder: the involvement of 1,2-diacylglycerol. 38
12798429 2003
26
Functional disorders of the oxidative phosphorylation system in the heart mitochondria of mice with juvenile visceral steatosis. 38
12612434 2003
27
Changes in distinct species of 1,2-diacylglycerol in cardiac hypertrophy due to energy metabolic disorder. 38
12504818 2003
28
Carnitine transport: pathophysiology and metabolism of known molecular defects. 38
12889657 2003
29
Hyperammonemia in carnitine-deficient adult JVS mice used by starvation. 38
12602512 2002
30
Novel mRNA molecules are induced in hypertrophied ventricles of carnitine-deficient mice and belong to a family of up-regulated gene in cells overexpressing c-erbB-2. 38
12359334 2002
31
Age-associated cardiomyopathy in heterozygous carrier mice of a pathological mutation of carnitine transporter gene, OCTN2. 38
12084797 2002
32
A heterozygote phenotype is present in the jvs +/- mutant mouse livers. 38
12175785 2002
33
Activities of cytochrome p450 enzymes in liver and kidney microsomes from systemic carnitine deficiency mice with a gene mutation of carnitine/organic cation transporter. 38
15618652 2002
34
Calcineurin inhibitor attenuates cardiac hypertrophy due to energy metabolic disorder. 38
11773940 2001
35
Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. 38
11739607 2001
36
Antioxidant changes in the hypertrophied heart due to energy metabolic disorder. 38
11605989 2001
37
Carnitine transport by organic cation transporters and systemic carnitine deficiency. 38
11509010 2001
38
Effect of gamma-butyrobetaine on fatty liver in juvenile visceral steatosis mice. 38
11341370 2001
39
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. 38
11160873 2001
40
Genomic organization and mapping of mouse CDV (carnitine deficiency-associated gene expressed in ventricle)-1 and its related CDV-1R gene. 38
11130971 2000
41
Antagonizing effect of AP-1 on glucocorticoid induction of urea cycle enzymes: a study of hyperammonemia in carnitine-deficient, juvenile visceral steatosis mice. 38
11136545 2000
42
The signaling pathway of cardiotrophin-1 is not activated in hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. 38
10904873 2000
43
Involvement of a cis-acting element in the suppression of carbamoyl phosphate synthetase I gene expression in the liver of carnitine-deficient mice. 38
10562461 1999
44
Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. 38
10498652 1999
45
Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. 38
10087008 1999
46
Dysfunctions of the epididymis as a result of primary carnitine deficiency in juvenile visceral steatosis mice. 38
10100867 1999
47
Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. 38
9916797 1999
48
Catecholamine metabolism inhibitors and receptor blockades only partially suppress cardiac hypertrophy of juvenile visceral steatosis mice with systemic carnitine deficiency. 38
10210276 1999
49
Cardiomegaly in the juvenile visceral steatosis (JVS) mouse is reduced with acute elevation of heart short-chain acyl-carnitine level after L-carnitine injection. 38
10025944 1999
50
Pyruvate dehydrogenase kinase 4 mRNA is increased in the hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. 38
10609898 1999

Variations for Visceral Steatosis

Expression for Visceral Steatosis

Search GEO for disease gene expression data for Visceral Steatosis.

Pathways for Visceral Steatosis

GO Terms for Visceral Steatosis

Cellular components related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial outer membrane GO:0005741 8.62 CPT1B CPT1A

Biological processes related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.32 CPT1B CPT1A
2 fatty acid metabolic process GO:0006631 9.26 CPT1B CPT1A
3 fatty acid beta-oxidation GO:0006635 9.16 CPT1B CPT1A
4 carnitine shuttle GO:0006853 8.96 CPT1B CPT1A
5 carnitine metabolic process GO:0009437 8.62 CPT1B CPT1A

Molecular functions related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity, transferring acyl groups GO:0016746 8.96 CPT1B CPT1A
2 carnitine O-palmitoyltransferase activity GO:0004095 8.62 CPT1B CPT1A

Sources for Visceral Steatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....